- Home
- TELA vs ALGS Comparison
TELA vs ALGS Comparison
Compare TELA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TELA | ALGS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 34.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TELA | ALGS |
|---|---|---|
| Price | $1.29 | $5.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.00 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 338.7K | 48.7K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.59 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,275,000.00 | $2,186,000.00 |
| Revenue This Year | $10.23 | $32.20 |
| Revenue Next Year | $14.26 | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $3.98 |
| 52 Week High | $1.60 | $13.69 |
Technical Indicators
Market Signals| Indicator | TELA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 77.09 | 45.40 |
| Support Level | $0.61 | $4.80 |
| Resistance Level | N/A | $5.94 |
| Average True Range (ATR) | 0.11 | 0.42 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 88.54 | 36.81 |
Price Performance
Historical ComparisonAbout TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.